Cited by 401Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 100 of the 103 references it cites were found in a registry or an index.

Protein phosphatase 2A: a target for anticancer therapy

Open access

Perrotti, Danilo, Neviani, Paolo·2013·The Lancet Oncology

DOI 10.1016/s1470-2045(12)70558-2PMC PMC3913484

Open this paper in CoChat — free account

Abstract

Protein phosphatase 2A (PP2A), one of the main serine-threonine phosphatases in mammalian cells, maintains cell homoeostasis by counteracting most of the kinase-driven intracellular signalling pathways. Unrestrained activation of oncogenic kinases together with inhibition of tumour suppressors is often required for development of cancer. PP2A has been shown to be genetically altered or functionally inactivated in many solid cancers and leukaemias, and is therefore a tumour suppressor. For example, the phosphatase activity of PP2A is suppressed in chronic myeloid leukaemia and other malignancies characterised by aberrant activity of oncogenic kinases. Preclinical studies show that pharmacological restoration of PP2A tumour-suppressor activity by PP2A-activating drugs (eg, FTY720) effectively antagonises cancer development and progression. Here, we discuss PP2A as a druggable tumour suppressor in view of the possible introduction of PP2A-activating drugs into anticancer therapeutic protocols.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70558-2

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma
Omar, H. A., Chou, C.-C., Berman-Booty, L. D., Ma, Y., Hung, J., Wang, D.-S., Kogure, T., Patel, T. C., Terracciano, L., Muthusamy, N., et al. (2011) · Hepatology · doi:10.1002/hep.24293 · Cited by 74
Retracted
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Oncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,181
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,028
Bcl-2 family proteins and cancer
Yip, K. W., & Reed, J. C. (2008) · Oncogene · doi:10.1038/onc.2008.307 · Cited by 913
Ubiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 608
Self-citation
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H. C., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 481
Self-citation
The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479
Greatwall Phosphorylates an Inhibitor of Protein Phosphatase 2Α That Is Essential for Mitosis
Mochida, S., Maslen, S., Skehel, M. J., & Hunt, T. (2010) · Science · doi:10.1126/science.1195689 · Cited by 427
Chronic myeloid leukemia: mechanisms of blastic transformation
Perrotti, D., Jamieson, C. H. M., Goldman, J. M., & Skórski, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41246 · Cited by 402
Self-citation
PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)
Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia
Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31095 · Cited by 337
Self-citation
Live-cell imaging RNAi screen identifies PP2A–B55α and importin-β1 as key mitotic exit regulators in human cells
Schmitz, M. H. A., Held, M., Janssens, V., Hutchins, J. R. A., Hudecz, O., Ivanova, E., Goris, J., Trinkle‐Mulcahy, L., Lamond, A. I., Poser, I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2092 · Cited by 324
Phosphatases: providing safe passage through mitotic exit
Wurzenberger, C., & Gerlich, D. W. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3149 · Cited by 305
Antagonism of Sphingosine-1-Phosphate Receptors by FTY720 Inhibits Angiogenesis and Tumor Vascularization
LaMontagne, K. R., Littlewood-Evans, A. J., Schnell, C., O’Reilly, T., Wyder, L., Sánchez, T., Probst, B., Butler, J., Wood, A. W., Liau, G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2001 · Cited by 302
Protein Kinases and Phosphatases in the Control of Cell Fate
Bononi, A., Agnoletto, C., Marchi, E. D., Marchi, S., Patergnani, S., Bonora, M., Giorgi, C., Missiroli, S., Poletti, F., Rimessi, A., et al. (2011) · Enzyme Research · doi:10.4061/2011/329098 · Cited by 294
Induction of cancer cell apoptosis by α‐tocopheryl succinate: molecular pathways and structural requirements
Neužil, J., WEBER, T., SCHRÖDER, A., Lü, M., Ostermann, G., Gellert, N., Mayne, G. C., Olejnicka, B. T., Nègre‐Salvayre, A., Štícha, M., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0251com · Cited by 284
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia
Vlierberghe, P. V., van Grotel, M., Tchinda, J., Lee, C., Beverloo, H. B., van der Spek, P. J., Stubbs, A., Cools, J., Nagata, K., Fornerod, M. W. J., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111872 · Cited by 226
Identification of a New Family of Protein Phosphatase 2A Regulatory Subunits
McCright, B., & Virshup, D. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.44.26123 · Cited by 222
Identification of PP2A Complexes and Pathways Involved in Cell Transformation
Sablina, A. A., Hector, M., Colpaert, N., & Hahn, W. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2855 · Cited by 193
Molecular Identification of I1PP2A, a Novel Potent Heat-Stable Inhibitor Protein of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Biochemistry · doi:10.1021/bi960581y · Cited by 178
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.
Adachi, Y., Pavlakis, G. N., & Copeland, T. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42162-4 · Cited by 175
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia
Cristóbal, I., Blanco, F. J., García-Ortí, L., Marcotegui, N., Vicente, C., Rifón, J., Novo, F. J., Bandrés, E., Calasanz, M. J., Bernabéu, C., et al. (2009) · Blood · doi:10.1182/blood-2009-06-227363 · Cited by 172
Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
Switzer, C. H., Cheng, R. Y. S., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P. (2011) · Oncogene · doi:10.1038/onc.2010.622 · Cited by 171
A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation
Ito, A., Kataoka, T. R., Watanabe, M., Nishiyama, K., Mazaki, Y., Sabe, H., Kitamura, Y., & Nojima, H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.562 · Cited by 159
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
Liu, Q., Zhao, X. B., Frissora, F. W., Ma, Y., Santhanam, R., Jarjoura, D. G., Lehman, A., Perrotti, D., Chen, C., Dalton, J. T., et al. (2007) · Blood · doi:10.1182/blood-2006-10-053884 · Cited by 146
Self-citation
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect
Cristóbal, I., García-Ortí, L., Cirauqui, C., Alonso, M. M., Calasanz, M. J., & Odero, M. D. (2011) · Leukemia · doi:10.1038/leu.2010.294 · Cited by 138
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target
Christensen, D. J., Chen, Y., Oddo, J., Matta, K. M., Neil, J. E., Davis, E. D., Volkheimer, A. D., Lanasa, M. C., Friedman, D. R., Goodman, B. K., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351072 · Cited by 133
Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
Roberts, K. G., Smith, A. M., McDougall, F. K., Carpenter, H., Horan, M. P., Neviani, P., Powell, J. A., Thomas, D., Guthridge, M. A., Perrotti, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2544 · Cited by 133
Self-citation
Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells
Kar, S., Palit, S., Ball, W. B., & Das, P. K. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0715-4 · Cited by 130
Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene
Ruediger, R., Pham, H. T., & Walter, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204279 · Cited by 127
Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia
Cristóbal, I., García-Ortí, L., Cirauqui, C., Cortés-Lavaud, X., Garcı́a-Sánchez, A., Calasanz, M. J., & Odero, M. D. (2011) · Haematologica · doi:10.3324/haematol.2011.050542 · Cited by 126
Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A
Christensen, D. J., Ohkubo, N., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., Colton, C. A., & Vitek, M. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002847 · Cited by 125
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122
Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A
Salas, A., Ponnusamy, S., Senkal, C. E., Meyers‐Needham, M., Selvam, S. P., Saddoughi, S. A., Apohan, E., Sentelle, R. D., Smith, C. D., Gault, C. R., et al. (2011) · Blood · doi:10.1182/blood-2010-08-300772 · Cited by 122
Self-citation
FTY720 Analogues as Sphingosine Kinase 1 Inhibitors
Lim, K. G., Tonelli, F., Li, Z., Lu, X., Bittman, R., Pyne, S., & Pyne, N. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.220756 · Cited by 118
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias
Perrotti, D., & Neviani, P. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9119-x · Cited by 117
Self-citation
Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
Ingwersen, J., Aktaş, O., Küry, P., Kieseier, B. C., Boyко, A., & Hartung, H. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.05.005 · Cited by 113
Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients
Samanta, A. K., Chakraborty, S. N., Wang, Y., Kantarjian, H. M., Sun, X., Hood, J. D., Perrotti, D., & Arlinghaus, R. B. (2009) · Oncogene · doi:10.1038/onc.2009.7 · Cited by 113
Self-citation
Induction of Apoptosis in Human Bladder Cancer Cells In Vitro and In Vivo Caused by FTY720 Treatment
Azuma, H., Takahara, S., Horie, S., Muto, S., Otsuki, Y., & Katsuoka, Y. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000064938.32318.91 · Cited by 109
Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes
Shah, M. V., Zhang, R., Irby, R., Kothapalli, R., Liu, X., Arrington, T., Frank, B. C., Lee, N. H., & Loughran, T. P. (2008) · Blood · doi:10.1182/blood-2007-11-121871 · Cited by 109
Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+- De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway
Park, M. A., Mitchell, C., Zhang, G., Yacoub, A., Allegood, J. C., Häussinger, D., Reinehr, R., Larner, A. C., Spiegel, S., Fisher, P. B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0999 · Cited by 102
Prognostic role of CIP2A expression in serous ovarian cancer
Böckelman, C., Lassus, H., Hemmes, A., Leminen, A., Westermarck, J., Haglund, C., Bützow, R., & Ristimäki, A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.346 · Cited by 100
FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance
Yasui, H., Hideshima, T., Raje, N. S., Roccaro, A. M., Shiraishi, N., Kumar, S. K., Hamasaki, M., Ishitsuka, K., Tai, Y., Podar, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0850 · Cited by 99
Somatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas
Shih, I., Panuganti, P. K., Kuo, K., Mao, T., Kuhn, E., Jones, S., Velculescu, V. E., Kurman, R. J., & Wang, T. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.009 · Cited by 99
The role of oncogenic kinases in human cancer (Review).
Tsatsanis, C., & Spandidos, D. A. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.5.6.583 · Cited by 98
FTY720: A Promising Agent for Treatment of Metastatic Hepatocellular Carcinoma
Lee, T. K., Man, K., Ho, J. W., Wang, X. H., Poon, R. T. P., Xu, Y. Y., Ng, K. T., Chu, A. C., Sun, C. K.-W., Ng, I. O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0447 · Cited by 98
Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice
Ruediger, R., Ruiz, J., & Walter, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05744-11 · Cited by 98
The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Janssens, V., & Rebollo, A. (2012) · Current Molecular Medicine · doi:10.2174/156652412799218930 · Cited by 95
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients
Ruvolo, P. P., Qui, Y. H., Coombes, K. R., Zhang, N., Ruvolo, V. R., Borthakur, G. M., Konopleva, M. Y., Andreeff, M., & Kornblau, S. M. (2011) · Leukemia · doi:10.1038/leu.2011.146 · Cited by 89
CIP2A expression is increased in prostate cancer
Vaarala, M. H., Väisänen, M., & Ristimaki, A. P. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-136 · Cited by 87
Analysis of 11q22–q23 deletion target genes in B-cell chronic lymphocytic leukaemia: Evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B
Kalla, C., Scheuermann, M. O., Kube, I., Schlotter, M., Mertens, D., Döhner, H., Stilgenbauer, S., & Lichter, P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.02.005 · Cited by 84
Overexpression of the Protein Phosphatase 2A Regulatory Subunit Bγ Promotes Neuronal Differentiation by Activating the MAP Kinase (MAPK) Cascade
Strack, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203767200 · Cited by 81
Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway
McConnell, J. L., Gomez, R. J., McCorvey, L. R. A., Law, B. K., & Wadzinski, B. E. (2007) · Oncogene · doi:10.1038/sj.onc.1210406 · Cited by 80
FTY720, a fungus metabolite, inhibits in vivo growth of androgen‐independent prostate cancer
Chua, C. W., Lee, D. T., Ling, M., Zhou, C., Man, K., Ho, J., Chan, F. L., Wang, X., & Wong, Y. C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21243 · Cited by 79
FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation
Lee, T. K., Man, K., Ho, J. W., Sun, C. K.-W., Ng, K. T., Wang, X. H., Wong, Y. C., Ng, I. O., Xu, R., & Fan, S. T. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh250 · Cited by 79
Protein Phosphatase 2A Negatively Regulates Eukaryotic Initiation Factor 4E Phosphorylation and eIF4F Assembly through Direct Dephosphorylation of Mnk and eIF4E
Li, Y., Yue, P., Deng, X., Ueda, T., Fukunaga, R., Khuri, F. R., & Sun, S. (2010) · Neoplasia · doi:10.1593/neo.10704 · Cited by 78
Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity
Al-Murrani, S. W. K., Woodgett, J. R., & Damuni, Z. (1999) · Biochemical Journal · doi:10.1042/bj3410293 · Cited by 78
FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells
Wallington-Beddoe, C. T., Hewson, J. W., Bradstock, K. F., & Bendall, L. J. (2011) · Autophagy · doi:10.4161/auto.7.7.15154 · Cited by 76
Effects of Phosphorylation of Immunomodulatory Agent FTY720 (Fingolimod) on Antiproliferative Activity against Breast and Colon Cancer Cells
Nagaoka, Y., Otsuki, K., Fujita, T., & Uesato, S. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1177 · Cited by 73
Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.004 · Cited by 68
CIP2A is over‐expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation
Wang, J., LI, W., Li, L., Yu, X., Jia, J., & Chen, C. (2011) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2010.01288.x · Cited by 66
CIP2A overexpression is associated with c-Myc expression in colorectal cancer
Böckelman, C., Koskensalo, S., Hagström, J., Lundin, M., Ristimaki, A. P., & Haglund, C. H. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.18922 · Cited by 64
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells
Lin, Y., Chen, K., Chen, C., Cheng, A., & Chen, K.-F. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.01.012 · Cited by 64
PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates
Kurimchak, A., & Graña, X. (2012) · Gene · doi:10.1016/j.gene.2012.02.015 · Cited by 58
Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12)
Panagopoulos, I., Kerndrup, G. B., Carlsen, N., Strömbeck, B., Isaksson, M., & Johansson, B. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06410.x · Cited by 57
ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ–PP2A
Shouse, G., Nobumori, Y., Panowicz, M. J., & Liu, X. (2011) · Oncogene · doi:10.1038/onc.2011.95 · Cited by 53
The PP2A inhibitor SET regulates natural killer cell IFN-γ production
Trotta, R., Ciarlariello, D., Col, J. D., Allard, J., Neviani, P., Santhanam, R., Mao, H. C., Becknell, B., Yu, J., Ferketich, A. K., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070419 · Cited by 53
Self-citation
Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity.
Azuma, H., Horie, S., Muto, S., Otsuki, Y., Matsumoto, K., Morimoto, J., Gotoh, R., Okuyama, Ä., Suzuki, S., Katsuoka, Y., et al. (2003) · PubMed · Cited by 51
PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: A mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment
Guénin, S., Schwartz, L. H., Morvan, D., Steyaert, J., Poignet, A., Madelmont, J., & Demidem, A. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.49 · Cited by 49
PP2A and Alzheimer Disease
Torrent, L., & Ferrer, I. (2012) · Current Alzheimer Research · doi:10.2174/156720512799361682 · Cited by 49
PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells
Mannava, S., Omilian, A. R., Wawrzyniak, J. A., Fink, E. E., Zhuang, D., Miecznikowski, J. C., Marshall, J. R., Soengas, M. S., Sears, R. C., Morrison, C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.339 · Cited by 46
Ceramide Produces Apoptosis Through Induction of p27kip1by Protein Phosphatase 2A-dependent Akt Dephosphorylation in PC-3 Prostate Cancer Cells
Kim, S. W., Kim, H. J., Chun, Y. J., & Kim, M. Y. (2010) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2010.511553 · Cited by 45
FLT3/ITD Mutation Signaling Includes Suppression of SHP-1
Chen, P., Levis, M. J., Brown, P. A., Kim, K.-T., Allebach, J., & Small, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411974200 · Cited by 44
CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis
Xu, P., Xu, X., Huang, Q., Zhang, Z., & Zhang, Y. (2011) · Medical Oncology · doi:10.1007/s12032-011-0053-3 · Cited by 44
Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
Hu, Z., Pan, X., Wu, F., Ma, L., Liu, D., Liu, Y., Feng, T., Meng, F., Liu, X., Jiang, Q., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006257 · Cited by 43
Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia
Liao, A., Broeg, K., Fox, T. E., Tan, S., Watters, R. J., Shah, M. V., Zhang, L. Q., Li, Y., Ryland, L. K., Yang, J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-331447 · Cited by 41
The B56γ3 Regulatory Subunit of Protein Phosphatase 2A (PP2A) Regulates S Phase-specific Nuclear Accumulation of PP2A and the G1 to S Transition
Lee, T.-Y., Lai, T.-Y., Lin, S.-C., Wu, C.-W., Ni, I.-F., Yang, Y.-S., Hung, L., Law, B. K., & Chiang, C.-W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094953 · Cited by 41
Protein Phosphatase 2A Regulates Interleukin-2 Receptor Complex Formation and JAK3/STAT5 Activation
Ross, J. A., Cheng, H., Nagy, Z. S., Frost, J. A., & Kirken, R. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053843 · Cited by 39
SET-induced calcium signaling and MAPK/ERK pathway activation mediate dendritic cell-like differentiation of U937 cells
Kandilci, A., & Grosveld, G. C. (2005) · Leukemia · doi:10.1038/sj.leu.2403826 · Cited by 36
T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl‐2
Nagahara, Y., Ikekita, M., & Shinomiya, T. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704970 · Cited by 35
The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells
Trotta, R., Ciarlariello, D., Col, J. D., Mao, H. C., Chen, L., Briercheck, E. L., Yu, J., Zhang, J., Perrotti, D., & Caligiuri, M. A. (2010) · Blood · doi:10.1182/blood-2010-05-285130 · Cited by 34
Self-citation
Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers
Li, Y., Nie, C., Hu, L., Qin, Y., Liu, H.-B., Zeng, T., Chen, L., Fu, L., Deng, W., Chen, S.-P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0392 · Cited by 33
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma
Alinari, L., Baiocchi, R. A., & Prætorius-Ibba, M. (2012) · Autophagy · doi:10.4161/auto.19050 · Cited by 32
A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region
Baysal, B. E., Willett-Brozick, J. E., Taschner, P. E. M., Dauwerse, J., Devilee, P., & Devlin, B. (2001) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200585 · Cited by 31
FTY720: from bench to bedside
Kahan, B. D. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.01.092 · Cited by 26
Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation
Yuksel, S., Saydam, G., Uslu, R., Şanlı, U. A., Terzıoğlu, E., Büyükkeçeci, F., & Omay, S. B. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00147-3 · Cited by 26
Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma
Chou, H.-C., Chen, C., Lee, M., Lee, C., Huang, G., Yang, P., Lee, P., & Sheu, J. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.01.016 · Cited by 24
Transgenic expression of protein phosphatase 2A regulatory subunit B56γ disrupts distal lung differentiation
Everett, A. D., Kamibayashi, C., & Brautigan, D. L. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00262.2001 · Cited by 24
In Search of CML Stem Cells’ Deadly Weakness
Pellicano, F., Sinclair, A., & Holyoake, T. L. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0085-y · Cited by 22
A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,
Agarwal, A., MacKenzie, R. J., Oddo, J., Vitek, M. P., Christensen, D. J., & Druker, B. J. (2011) · Blood · doi:10.1182/blood.v118.21.3757.3757 · Cited by 14
Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells
Sebestyén, A. R., Hajdú, M., Kis, L., Barna, G., & Kopper, L. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.05.028 · Cited by 11
BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment
Neviani, P., Harb, J. G., Oaks, J. J., Walker, C. J., Santhanam, R., Paisie, C. A., Eiring, A. M., Zhang, B., Perazzona, B., Ma, Y., et al. (2010) · Blood · doi:10.1182/blood.v116.21.515.515 · Cited by 11
Self-citation
Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment
Neviani, P., Harb, J. G., Oaks, J. J., Walker, C. J., Santhanam, R., Paisie, C. A., Eiring, A. M., Zhang, B., Perazzona, B., Ma, Y., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-lb-109 · Cited by 4
Self-citation
PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives
Walker, C. J., Oaks, J. J., Neviani, P., Harb, J. G., Santhanam, R., Ma, Y., Marcucci, G., Brocklyn, J. R. V., Chen, C., Bittman, R., et al. (2010) · Blood · doi:10.1182/blood.v116.21.2901.2901 · Cited by 4
Self-citation
FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration
Oaks, J. J., Mukhopadhyay, A., Santhanam, R., Saddoughi, S. A., Neviani, P., Harb, J. G., Öğretmen, B., Bittman, R., Levine, R. L., Quintás‐Cardama, A., et al. (2011) · Blood · doi:10.1182/blood.v118.21.2494.2494 · Cited by 4
Self-citation

Sorted by citations

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Zhai, B., Hu, F., Jiang, X. L., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1043 · Cited by 286
Platelets reduce anoikis and promote metastasis by activating YAP1 signaling
Haemmerle, M., Taylor, M., Gutschner, T., Pradeep, S., Cho, M. S., Sheng, J., Lyons, Y., Nagaraja, A. S., Dood, R. L., Wen, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00411-z · Cited by 274
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Neviani, P., Harb, J. G., Oaks, J. J., Santhanam, R., Walker, C. J., Ellis, J. J., Ferenchak, G. J., Dorrance, A. M., Paisie, C. A., Eiring, A. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68951 · Cited by 227
Self-citation

See all 401

Authors: Perrotti, D., & Neviani, P.
Affiliations: The Ohio State University (US)
Corresponding author: Perrotti, Danilo
ORCID: Perrotti, Danilo
Neviani, Paolo
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2013-05
Volume: 14
Issue: 6
Pages: e229-e238
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(12)70558-2
PMC: PMC3913484
OpenAlex: W1987474302
Cited by: 400
References: 103
Citations by year: 2026: 13 · 2025: 17 · 2024: 16 · 2023: 33 · 2022: 31 · 2021: 26 · 2020: 33 · 2019: 35 · 2018: 29 · 2017: 37 · 2016: 62 · 2015: 29 · 2014: 28 · 2013: 11
FWCI: 3.99
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P50CA140158, R01CA163800, R01CA095512, P30CA016058)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: protein phosphatase 2A, tumour suppressor, cancer therapy, fingolimod, oncogenic kinase, serine/threonine phosphatase, chronic myeloid leukemia, therapeutic target
MeSH terms: Animals, Antineoplastic Agents, Enzyme Activation, Humans, Neoplasms, Drug Design, Signal Transduction, Enzyme Activators, Protein Phosphatase 2, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Protein phosphatase 2A: a target for anticancer therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks